Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOT-H: Dolutegravir vs Dolutegravir + Tenofovir for HTLV-1 Infection
NCT07555431Phase 2Recruiting
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dolutegravir, tenofovir disoproxil fumarate in Human T-lymphotropic virus type 1 infection. Started May 2026; status: recruiting.
02
Drugs
dolutegravirtenofovir disoproxil fumarate
03
Conditions
Human T-lymphotropic virus type 1 infection
Beyond the preview
Go deeper on NCT07555431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07555431.